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A common feature of cancer is a syn-
drome known as “cachexia,” which is a 
body-wasting syndrome, and which prom-
inently features skeletal muscle atrophy. 
The loss of skeletal muscle during cancer 
causes a profound fragility in the patient. 
This fragility complicates therapy and may 
accelerate death as a result of atrophy of 
the diaphragm muscle. Loss of function in 
the diaphragm is also the eventual cause 
of death in a series of conditions that have 
been thought to be distinct from atrophy 
syndromes: muscular dystrophies. In dys-
trophic settings, there is an obvious loss 
of structural patency, whereas in atrophy 
syndromes a similar structural perturba-
tion has not been previously appreciated; 
instead, it was thought that fibers merely 
decrease in size, without an obvious dis-
regulation in structure.
Components of the dystrophin glyco-
protein complex (DGC) have been shown 
to be mutated in Duchenne/Becker forms 
of skeletal muscle dystrophy. The DGC 
helps to anchor the muscle cytoskeleton 
to the cell membrane via dystrophin and 
its binding partners; on the surface of the 
muscle, α-dystroglycan, which is part 
of the DGC, binds laminin-2 in the extra-
cellular matrix (Ibraghimov-Beskrovnaya 
et al., 1992). Therefore, the DGC provides 
a means of communicating from the extra-
cellular matrix to the cytoskeleton. While 
the DGC may have originally been thought 
to play a purely structural role, it had been 
suggested that the complex may stimu-
late signaling pathways and thereby func-
tion as more than a structural element, 
since disruption of dystroglycan binding 
to laminin was shown to inhibit activation 
of Akt signaling (Langenbach and Rando, 
2002); these data were of particular inter-
est, since Akt had been previously shown 
to be sufficient to mediate skeletal muscle 
hypertrophy (Lai et al., 2004; Rommel et 
al., 2001). What was unclear from the pre-
vious finding was the mechanism by which 
laminin was signaling; for example, lam-
inin also stimulates activation of integrin 
receptors (Ignatius and Reichardt, 1988), 
and therefore it was quite reasonable to 
suppose that it was the integrin pathway, 
and not the DGC, that was mediating 
the signaling disruption. In this issue of 
Cancer Cell, a study is published that pro-
vides the critical evidence demonstrating 
that dystrophin itself is capable of mediat-
ing signals relevant to muscle atrophy and 
hypertrophy (Acharyya et al., 2005).
The signaling pathways mediating 
skeletal muscle atrophy have only recently 
begun to be defined. Protein breakdown 
increases during atrophy, and inhibition 
of the proteasome blocks these increas-
es (Tawa et al., 1997), suggesting that 
 ubiquitin-mediated proteolysis is required 
for the degradation increases seen dur-
ing atrophy—this idea was also supported 
by recent data that showed that treatment 
with the proteasome inhibitor Velcade can 
reduce muscle loss under atrophy condi-
tions (Krawiec et al., 2005). It is now appre-
ciated that ubiquitination is an exquisitely 
modulated process—specificity of protein 
substrates that are targeted for breakdown 
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Figure 1. signaling diagram illustrating skeletal 
muscle hypertrophy and atrophy signaling 
pathways
modulators that increase skeletal muscle 
mass are in green; proteins that mediate the 
loss of muscle mass and that are activated 
during atrophy are in red. A possible position 
for dystrophin is illustrated, since disruption of 
the Dgc was previously shown to result in a 
downregulation of Akt signaling, and since 
Akt is necessary to inhibit upregulation of the 
atrophy markers murF1 and mAFbx. in the cur-
rent study, maintenance of dystrophin is dem-
onstrated to block atrophy, and this effect is 
coincident with an inhibition of murF1 and 
mAFbx upregulation, thus giving support for 
the model as diagrammed. however, there 
are other possibilities, including a direct effect 
of dystrophin on the ubiquitin ligases; more 
study is required to conclusively demonstrate 
the mechanism mediating the dystrophin 
effect.
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by the proteasome is controlled by several 
hundred substrate-specific E3 ubiquitin 
ligases. Expression of two E3 ubiquitin 
ligases in particular increases signifi-
cantly in multiple models of skeletal mus-
cle atrophy: MuRF1 (Bodine et al., 2001) 
(for Muscle RING Finger 1) and MAFbx 
(Bodine et al., 2001) (for Muscle Atrophy 
F-box; also called atrogin-1 [Gomes et al., 
2001]). MuRF1 and MAFbx are more than 
strong markers of the atrophy process; 
knockout of either gene perturbs muscle 
atrophy—loss of MuRF1 results in spar-
ing of functional muscle under atrophy 
conditions (Bodine et al., 2001), whereas 
MAFbx is required for the maintenance 
of myofiber integrity during atrophy condi-
tions (our unpublished data).
As for signaling, MuRF1 was shown 
to be upregulated by the NF-κB pathway 
(Figure 1), which is activated by cachec-
tic agents that can induce atrophy, such 
as TNFα (Ladner et al., 2003). NF-κB in 
muscle is also activated by disuse (Hunter 
et al., 2002), indicating that it might play 
a role in physiological pathogenesis. 
Activation of the NF-κB pathway was dem-
onstrated to be sufficient to induce signifi-
cant atrophy, as measured by increases in 
in vivo amino acid excretion and tyrosine 
turnover in isolated muscles (Cai et al., 
2004), and blockade of the NF-κB path-
way can significantly inhibit the amount 
of atrophy seen in physiological settings 
such as denervation- and tumor-induced 
atrophy (Cai et al., 2004).
The transcriptional upregulation of 
MAFbx and MuRF1 that is seen under 
atrophy conditions can be antagonized 
by simultaneous treatment with the 
hypertrophy-inducing protein growth 
factor insulin-like growth factor 1 (IGF-1) 
(Sandri et al., 2004; Stitt et al., 2004), 
acting through the PI3K/Akt pathway; 
this finding demonstrated a novel role 
for Akt—in addition to stimulating skeletal 
muscle hypertrophy via activation of pro-
tein synthesis pathways, Akt stimulation 
could dominantly inhibit the induction of 
atrophy signaling (Figure 1). The mecha-
nism by which Akt inhibited MAFbx and 
MuRF1 upregulation was demonstrated 
to involve the FOXO family of transcrip-
tion factors (Sandri et al., 2004; Stitt 
et al., 2004). In myotubes, FOXO tran-
scription factors are excluded from the 
nucleus when phosphorylated by Akt, 
and translocate to the nucleus upon 
 dephosphorylation. The translocation and 
activity of FOXO transcription factors are 
required for upregulation of MuRF1 and 
MAFbx, a finding that was subsequently 
supported by the transgenic expression 
of FOXO1, which resulted in atrophic 
phenotype (Kamei et al., 2004).
In the current study, under atrophy 
conditions—in this case, atrophy was 
stimulated by introduction of a cachexia-
inducing tumor—there was a perturba-
tion of the myofibrillar membrane, which 
indicated a possible loss of structural 
integrity in the DGC; this was supported 
by the finding that the resultant atrophic 
muscle underwent a significant decrease 
in dystrophin levels (Acharyya et al., 
2005). The authors then asked whether 
wasting was enhanced by a lack of dys-
trophin, and therefore turned to the MDX 
mouse model of muscular dystrophy, in 
which dystrophin is mutated. While it was 
interesting that there was an enhanced 
loss of muscle mass in these animals, 
one might have argued that such a result 
was not surprising, since MDX muscle 
is damaged to begin with. However, the 
authors went further, and studied a trans-
genic animal that overexpressed dys-
trophin. Under atrophy conditions, there 
was significantly less muscle loss in the 
transgenic animal, indicating that main-
tenance of dystrophin levels is sufficient 
to inhibit a significant amount of muscle 
loss. The authors demonstrated that dys-
trophin was blocking atrophy by inhibiting 
the previously established atrophy path-
ways, since upregulation of MuRF1 and 
upregulation of MAFbx was also inhibited 
in the dystrophin transgenic relative to 
wild-type animals, under atrophy condi-
tions (Acharyya et al., 2005).
Since it has already been shown 
that Akt can block upregulation of 
MuRF1 and MAFbx, and that disruption 
of the DGC can block Akt, it is appeal-
ing to speculate that this is the pathway 
by which dystrophin is operating in the 
current study; while the authors suggest 
this possibility, they also hold out the 
option that dystrophin may be modulat-
ing other signaling mechanisms, includ-
ing an Akt-independent downregulation 
of MuRF1 and MAFbx. Further studies 
will help to distinguish among these 
possibilities, but for now it is of great 
interest to note that proteins that play 
important roles in maintaining skeletal 
muscle structural integrity may nonethe-
less also be important for cell signaling, 
and therefore should not be dismissed 
as pure architecture.
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